Prioritizing American safety over experimental technology, the Trump administration has revoked a $766 million contract with Moderna.
Specifically, the massive federal funding would have gone toward developing an mRNA vaccine against bird flu.
Health officials cited serious concerns about the under-tested mRNA platform that was rushed during the COVID pandemic.
The decision marks a significant shift away from questionable vaccine technologies that many Americans have grown deeply skeptical of.
The Department of Health and Human Services (HHS) informed Moderna that their multi-million dollar contract to develop a vaccine against pandemic influenza viruses, including the H5N1 bird flu, would be terminated immediately.
The funding, which included $176 million awarded in July 2024 and an additional $590 million in January 2025, was originally intended to support clinical trials and eventual production.
Department of Health and Human Services (HHS) Communications Director Andrew Nixon explained the decision in clear terms that will resonate with many Americans who questioned the safety of COVID vaccines.
“After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,” he said.
Nixon further emphasized the administration’s commitment to transparency:
“This is not simply about efficacy—it’s about safety, integrity, and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.”
The decision reflects Health Secretary Robert F. Kennedy Jr.’s skepticism about mRNA vaccine technology.
Under the new direction, HHS plans to redirect vaccine funding toward platforms with more established safety profiles and transparent data practices.
The liberal medical establishment immediately criticized the decision. Dr. Ashish Jha, who supported lockdowns and mandates during COVID, claimed: “This decision puts the lives and health of the American people at risk.”
Despite the contract being terminated, Moderna claimed to have positive interim results from a small study involving just 300 healthy adults.
The company says it will “explore alternative paths” for the vaccine program, likely seeking private funding.
The H5N1 bird flu has infected dairy herds and poultry farms across America, with about 70 human cases reported.
Unlike COVID-19, H5N1 has not shown signs of easy human-to-human transmission.
The contract cancellation represents a victory for fiscal responsibility and medical freedom advocates.
By redirecting funds away from questionable mRNA technology, the Trump administration has demonstrated its commitment to protecting Americans from potential pandemic threats and ensuring that vaccines meet the highest safety and efficacy standards.
